Vivek Subbiah, MD

The panel shares clinical pearls for community oncologists treating small cell lung cancer.

Taofeek Owonikoko, MD, PhD, highlights investigational agents and ongoing clinical trials in SCLC he looks forward to.

Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.

Dr Jared Weiss presents the profile of a 70-year-old male patient with SCLC who received chemotherapy in the second line setting for discussion to the panel.

Dr Vivek Subbiah explains the clinical trial data that led to the approval of lurbinectedin for SCLC treatment.

The panel discusses the second line treatment options in SCLC and how they choose among the various options based on patient and disease characteristics.

Vivek Subbiah, MD, MPH, presents the patient profile of a 60-year-old man with SCLC who progressed on frontline therapy.

Dr Charles Rudin highlights other notable clinical trials and real-world studies in patients with SCLC in the frontline setting.

Dr Charu Aggarwal shares data from the IMpower133 trial of atezolizumab plus chemotherapy for SCLC, and how to select the appropriate frontline therapy.

Vivek Subbiah, MD, analyzes adverse events observed with durvalumab plus chemotherapy in patients with SCLC and how they can be managed.

Jared Weiss, MD, reviews data from the CASPIAN trial of durvalumab plus chemotherapy in patients with extensive-stage small cell lung cancer.

Charu Aggarwal, MD, MPH, presents the profile of a patient with small cell lung cancer with brain metastases to spark a discussion on treatment approaches in the frontline setting.

The panel discusses how the field of small cell lung cancer treatment has changed in recent years.

Charles Rudin, MD, PhD, explains the prognostic staging systems used for small cell lung cancer.

Drs Owonikoko and Weiss provide a brief overview of small cell lung cancer and the vital importance of an early diagnosis to improve patient outcomes.

Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.